Edit
Aeglea BioTherapeutics, Inc.
https://www.aegleabio.com/Last activity: 05.08.2021
Active - Reference to Aeglea BioTherapeutics
Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases
Location: United States, Texas, Austin
Total raised: $94M
Investors 3
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.04.2016 | - | $50M | - |
| 23.03.2015 | Series B | $44M | - |
Mentions in press and media 11
| Date | Title | Description |
| 05.08.2021 | Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights | |
| 06.05.2021 | Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency | |
| 01.12.2020 | Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria | |
| 24.11.2020 | Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference | |
| 06.02.2019 | Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering | - |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 08.04.2016 | Austin-based Aeglea BioTherapeutics Goes Public and Raises $50 Million | Aeglea BioTherapeutics went public on the NASDAQ Stock Market Thursday at $10 a share with an Initial Public Offering bringing in $50 million. |
| 05.08.2015 | Ten Life Sciences Companies to Watch in Central Texas | |
| 27.03.2015 | Funding roundup - week ending 3/27/15 | Accel Partners, Falcon Social, Augmented Pixels, Socratic, iAngels, Realm, Hedvig, ZipMatch, Skycure (Come mingle with hundreds of top venture capitalists representing $10B-plus in capital under management, including Khosla Ventures, Greylo... |
| 23.03.2015 | Aeglea Biotherapeutics Raises $44M in Series B Funding | Aeglea Biotherapeutics , an Austin, Texas-based biopharmaceutical company focused on treating tumor metabolism, raised $44m in Series B funding. The round was led by existing backers Lilly Ventures and Novartis Venture Fund with participati... |
Show more